🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCagriSema (amylin + semaglutide) — REDEFINE Phase 3 results Page 3

CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results

Dr.Martinez Sun, Jun 7, 2026 at 10:19 AM 20 replies 606 viewsPage 3 of 4
adam_van
Member
212
890
Nov 2024
Vancouver, CA
Jun 7, 2026 at 2:36 PM#11
TinaHashiRN said:
The mechanism that matters here is not stomach emptying, it is central.

This answered a question I did not know how to ask.

Last edited: Jun 7, 2026 at 6:36 PM
28 3FranDenver, Dr.BariatricHTX, LindaRN_retired and 25 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Jun 7, 2026 at 5:58 PM#12

Adding the clinical framing, because it changes how the question reads. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

27 2KristenIndy, MarkLI_maint, Dr.PeteFamMed and 24 others
Reply Quote Save Share Report
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Jun 7, 2026 at 9:21 PM#13
JenPlateau said:
The dose-response is real but shallow at the top.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Happy to go further on any of that.

26 1Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 23 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Jun 8, 2026 at 12:43 AM#14

Adding the numbers, since they settle part of this. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

Ask again with the specifics and you will get a better answer than this one.

Last edited: Jun 8, 2026 at 3:43 AM
25 0lori_vegas, Dr.PulmRoch, maya_sedona and 22 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 8, 2026 at 4:05 AM#15

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Carry on.

24 24PurityPaulOR, MaxMetOK, MounjBrad and 21 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
Survodutide (GCG/GLP-1) — MASH and obesity trial results16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register